Open AccessNanoparticle Agent CRLX101 Overcomes Antiangiogenic Drug Resistance in Early Trials
Author(s) -
Kurt Samson
Publication year - 2014
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000441983.19391.1b
Subject(s) - bevacizumab , medicine , cancer , metastasis , oncology , drug resistance , hypoxia (environmental) , angiogenesis , cancer cell , drug , cancer drugs , cancer research , pharmacology , chemotherapy , biology , microbiology and biotechnology , chemistry , organic chemistry , oxygen